Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype

NCT03718767 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

62

Enrollment

NIH

Sponsor class

Conditions

Glioma
Glioblastoma
High Grade Glioma
Low Grade Glioma
Malignant Glioma

Interventions

DRUG: Nivolumab

Sponsor

National Cancer Institute (NCI)